Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Pegfilgrastim Biosimilar Market Research Report 2026

Global Pegfilgrastim Biosimilar Market Research Report 2026

Industry: Pharma & Healthcare

Published Date: 2026-04-21

Pages: 108 Pages

Report ld: 6599112

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Pegfilgrastim Biosimilar Market Size(US$)

CAGR 2026-2032

6.8%

Market Size,2032

USD 2,877

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 1,938 million

Market Forecast in 2032(Value)

US$ 2,877 million

CAGR

6.8%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Pegfilgrastim Biosimilar market was valued at US$ 1827 million in 2025 and is anticipated to reach US$ 2877 million by 2032, at a CAGR of 6.8% from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Pegfilgrastim Biosimilar competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report delivers a comprehensive overview of the global Pegfilgrastim Biosimilar market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pegfilgrastim Biosimilar. The Pegfilgrastim Biosimilar market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Pegfilgrastim Biosimilar market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Pegfilgrastim Biosimilar manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

MARKET SEGMENTATION

By Company

Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy’s Laboratories

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Chemotherapy Treatment
Transplantation

Segment by Application

Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Provides a detailed analysis of the competitive landscape for Pegfilgrastim Biosimilar manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.

Chapter 3: Examines Pegfilgrastim Biosimilar sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.

Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.

Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.

Chapter 7: Reviews the industry value chain, including upstream and downstream segments.

Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.

Chapter 9: Summarizes the key findings and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Pegfilgrastim Biosimilar Market Overview

1.1 Product Definition

1.2 Pegfilgrastim Biosimilar by Type

1.2.1 Global Pegfilgrastim Biosimilar Market Value by Type: 2025 vs 2032

1.2.2 Chemotherapy Treatment

1.2.3 Transplantation

1.3 Pegfilgrastim Biosimilar by Application

1.3.1 Global Pegfilgrastim Biosimilar Market Value by Application: 2025 vs 2032

1.3.2 Hospital Pharmacies

1.3.3 Mail-Order Pharmacies

1.3.4 Retail Pharmacies

1.4 Global Pegfilgrastim Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Pegfilgrastim Biosimilar Revenue 2021–2032

1.4.2 Global Pegfilgrastim Biosimilar Sales 2021–2032

1.4.3 Global Pegfilgrastim Biosimilar Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 Pegfilgrastim Biosimilar Market Competition by Manufacturers

2.1 Global Pegfilgrastim Biosimilar Sales Market Share by Manufacturers (2021–2026)

2.2 Global Pegfilgrastim Biosimilar Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Pegfilgrastim Biosimilar Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Pegfilgrastim Biosimilar, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Pegfilgrastim Biosimilar, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Pegfilgrastim Biosimilar, Product Types and Applications

2.7 Global Key Manufacturers of Pegfilgrastim Biosimilar, Date of Entry into the Industry

2.8 Global Pegfilgrastim Biosimilar Market Competitive Situation and Trends

2.8.1 Global Pegfilgrastim Biosimilar Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Pegfilgrastim Biosimilar Players Market Share by Revenue

2.8.3 Global Pegfilgrastim Biosimilar Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Pegfilgrastim Biosimilar Market Scenario by Region

3.1 Global Pegfilgrastim Biosimilar Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Pegfilgrastim Biosimilar Sales by Region: 2021–2032

3.2.1 Global Pegfilgrastim Biosimilar Sales by Region: 2021–2026

3.2.2 Global Pegfilgrastim Biosimilar Sales by Region: 2027–2032

3.3 Global Pegfilgrastim Biosimilar Revenue by Region: 2021–2032

3.3.1 Global Pegfilgrastim Biosimilar Revenue by Region: 2021–2026

3.3.2 Global Pegfilgrastim Biosimilar Revenue by Region: 2027–2032

3.4 North America Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.4.1 North America Pegfilgrastim Biosimilar Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Pegfilgrastim Biosimilar Sales by Country (2021–2032)

3.4.3 North America Pegfilgrastim Biosimilar Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.5.1 Europe Pegfilgrastim Biosimilar Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Pegfilgrastim Biosimilar Sales by Country (2021–2032)

3.5.3 Europe Pegfilgrastim Biosimilar Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Pegfilgrastim Biosimilar Market Facts & Figures by Region

3.6.1 Asia Pacific Pegfilgrastim Biosimilar Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Pegfilgrastim Biosimilar Sales by Region (2021–2032)

3.6.3 Asia Pacific Pegfilgrastim Biosimilar Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Pegfilgrastim Biosimilar Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Pegfilgrastim Biosimilar Sales by Country (2021–2032)

3.7.3 Latin America Pegfilgrastim Biosimilar Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Pegfilgrastim Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Pegfilgrastim Biosimilar Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Pegfilgrastim Biosimilar Sales by Country (2021–2032)

3.8.3 Middle East and Africa Pegfilgrastim Biosimilar Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Pegfilgrastim Biosimilar Sales by Type (2021–2032)

4.1.1 Global Pegfilgrastim Biosimilar Sales by Type (2021–2026)

4.1.2 Global Pegfilgrastim Biosimilar Sales by Type (2027–2032)

4.1.3 Global Pegfilgrastim Biosimilar Sales Market Share by Type (2021–2032)

4.2 Global Pegfilgrastim Biosimilar Revenue by Type (2021–2032)

4.2.1 Global Pegfilgrastim Biosimilar Revenue by Type (2021–2026)

4.2.2 Global Pegfilgrastim Biosimilar Revenue by Type (2027–2032)

4.2.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2021–2032)

4.3 Global Pegfilgrastim Biosimilar Price by Type (2021–2032)

5 Segment by Application

5.1 Global Pegfilgrastim Biosimilar Sales by Application (2021–2032)

5.1.1 Global Pegfilgrastim Biosimilar Sales by Application (2021–2026)

5.1.2 Global Pegfilgrastim Biosimilar Sales by Application (2027–2032)

5.1.3 Global Pegfilgrastim Biosimilar Sales Market Share by Application (2021–2032)

5.2 Global Pegfilgrastim Biosimilar Revenue by Application (2021–2032)

5.2.1 Global Pegfilgrastim Biosimilar Revenue by Application (2021–2026)

5.2.2 Global Pegfilgrastim Biosimilar Revenue by Application (2027–2032)

5.2.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2021–2032)

5.3 Global Pegfilgrastim Biosimilar Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Novartis

6.1.1 Novartis Company Information

6.1.2 Novartis Description and Business Overview

6.1.3 Novartis Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Novartis Pegfilgrastim Biosimilar Product Portfolio

6.1.5 Novartis Recent Developments/Updates

6.2 Mylan

6.2.1 Mylan Company Information

6.2.2 Mylan Description and Business Overview

6.2.3 Mylan Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Mylan Pegfilgrastim Biosimilar Product Portfolio

6.2.5 Mylan Recent Developments/Updates

6.3 Coherus BioSciences

6.3.1 Coherus BioSciences Company Information

6.3.2 Coherus BioSciences Description and Business Overview

6.3.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Coherus BioSciences Pegfilgrastim Biosimilar Product Portfolio

6.3.5 Coherus BioSciences Recent Developments/Updates

6.4 Mundipharma International

6.4.1 Mundipharma International Company Information

6.4.2 Mundipharma International Description and Business Overview

6.4.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Mundipharma International Pegfilgrastim Biosimilar Product Portfolio

6.4.5 Mundipharma International Recent Developments/Updates

6.5 Biocon

6.5.1 Biocon Company Information

6.5.2 Biocon Description and Business Overview

6.5.3 Biocon Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Biocon Pegfilgrastim Biosimilar Product Portfolio

6.5.5 Biocon Recent Developments/Updates

6.6 Intas Pharmaceuticals

6.6.1 Intas Pharmaceuticals Company Information

6.6.2 Intas Pharmaceuticals Description and Business Overview

6.6.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Portfolio

6.6.5 Intas Pharmaceuticals Recent Developments/Updates

6.7 Pfizer

6.7.1 Pfizer Company Information

6.7.2 Pfizer Description and Business Overview

6.7.3 Pfizer Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Pfizer Pegfilgrastim Biosimilar Product Portfolio

6.7.5 Pfizer Recent Developments/Updates

6.8 Dr Reddy’s Laboratories

6.8.1 Dr Reddy’s Laboratories Company Information

6.8.2 Dr Reddy’s Laboratories Description and Business Overview

6.8.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Portfolio

6.8.5 Dr Reddy’s Laboratories Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Pegfilgrastim Biosimilar Industry Chain Analysis

7.2 Pegfilgrastim Biosimilar Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Pegfilgrastim Biosimilar Production Mode & Process Analysis

7.4 Pegfilgrastim Biosimilar Sales and Marketing

7.4.1 Pegfilgrastim Biosimilar Sales Channels

7.4.2 Pegfilgrastim Biosimilar Distributors

7.5 Pegfilgrastim Biosimilar Customer Analysis

8 Pegfilgrastim Biosimilar Market Dynamics

8.1 Pegfilgrastim Biosimilar Industry Trends

8.2 Pegfilgrastim Biosimilar Market Drivers

8.3 Pegfilgrastim Biosimilar Market Challenges

8.4 Pegfilgrastim Biosimilar Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Pegfilgrastim Biosimilar Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Pegfilgrastim Biosimilar Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global Pegfilgrastim Biosimilar Market Competitive Situation by Manufacturers in 2025

Table 4. Global Pegfilgrastim Biosimilar Sales (K Units) of Key Manufacturers (2021–2026)

Table 5. Global Pegfilgrastim Biosimilar Sales Market Share by Manufacturers (2021–2026)

Table 6. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global Pegfilgrastim Biosimilar Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market Pegfilgrastim Biosimilar Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of Pegfilgrastim Biosimilar, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of Pegfilgrastim Biosimilar, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of Pegfilgrastim Biosimilar, Product Types and Applications

Table 12. Global Key Manufacturers of Pegfilgrastim Biosimilar, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Pegfilgrastim Biosimilar Companies by Tier (Tier 1, Tier 2, Tier 3), based on Pegfilgrastim Biosimilar Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Pegfilgrastim Biosimilar Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Pegfilgrastim Biosimilar Sales by Region (K Units), 2021–2026

Table 18. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2021–2026)

Table 19. Global Pegfilgrastim Biosimilar Sales by Region (K Units), 2027–2032

Table 20. Global Pegfilgrastim Biosimilar Sales Market Share by Region (2027–2032)

Table 21. Global Pegfilgrastim Biosimilar Revenue by Region (US$ Million), 2021–2026

Table 22. Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2021–2026)

Table 23. Global Pegfilgrastim Biosimilar Revenue by Region (US$ Million), 2027–2032

Table 24. Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2027–2032)

Table 25. North America Pegfilgrastim Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America Pegfilgrastim Biosimilar Sales by Country (K Units), 2021–2026

Table 27. North America Pegfilgrastim Biosimilar Sales by Country (K Units), 2027–2032

Table 28. North America Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2021–2026

Table 29. North America Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2027–2032

Table 30. Europe Pegfilgrastim Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe Pegfilgrastim Biosimilar Sales by Country (K Units), 2021–2026

Table 32. Europe Pegfilgrastim Biosimilar Sales by Country (K Units), 2027–2032

Table 33. Europe Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2021–2026

Table 34. Europe Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific Pegfilgrastim Biosimilar Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific Pegfilgrastim Biosimilar Sales by Region (K Units), 2021–2026

Table 37. Asia Pacific Pegfilgrastim Biosimilar Sales by Region (K Units), 2027–2032

Table 38. Asia Pacific Pegfilgrastim Biosimilar Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific Pegfilgrastim Biosimilar Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America Pegfilgrastim Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America Pegfilgrastim Biosimilar Sales by Country (K Units), 2021–2026

Table 42. Latin America Pegfilgrastim Biosimilar Sales by Country (K Units), 2027–2032

Table 43. Latin America Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa Pegfilgrastim Biosimilar Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa Pegfilgrastim Biosimilar Sales by Country (K Units), 2021–2026

Table 47. Middle East and Africa Pegfilgrastim Biosimilar Sales by Country (K Units), 2027–2032

Table 48. Middle East and Africa Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa Pegfilgrastim Biosimilar Revenue by Country (US$ Million), 2027–2032

Table 50. Global Pegfilgrastim Biosimilar Sales (K Units) by Type (2021–2026)

Table 51. Global Pegfilgrastim Biosimilar Sales (K Units) by Type (2027–2032)

Table 52. Global Pegfilgrastim Biosimilar Sales Market Share by Type (2021–2026)

Table 53. Global Pegfilgrastim Biosimilar Sales Market Share by Type (2027–2032)

Table 54. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Type (2021–2026)

Table 55. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Type (2027–2032)

Table 56. Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2021–2026)

Table 57. Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2027–2032)

Table 58. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Type (2021–2026)

Table 59. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Type (2027–2032)

Table 60. Global Pegfilgrastim Biosimilar Sales (K Units) by Application (2021–2026)

Table 61. Global Pegfilgrastim Biosimilar Sales (K Units) by Application (2027–2032)

Table 62. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2021–2026)

Table 63. Global Pegfilgrastim Biosimilar Sales Market Share by Application (2027–2032)

Table 64. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Application (2021–2026)

Table 65. Global Pegfilgrastim Biosimilar Revenue (US$ Million) by Application (2027–2032)

Table 66. Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2021–2026)

Table 67. Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2027–2032)

Table 68. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Application (2021–2026)

Table 69. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Application (2027–2032)

Table 70. Novartis Company Information

Table 71. Novartis Description and Business Overview

Table 72. Novartis Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 73. Novartis Pegfilgrastim Biosimilar Product

Table 74. Novartis Recent Developments/Updates

Table 75. Mylan Company Information

Table 76. Mylan Description and Business Overview

Table 77. Mylan Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 78. Mylan Pegfilgrastim Biosimilar Product

Table 79. Mylan Recent Developments/Updates

Table 80. Coherus BioSciences Company Information

Table 81. Coherus BioSciences Description and Business Overview

Table 82. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 83. Coherus BioSciences Pegfilgrastim Biosimilar Product

Table 84. Coherus BioSciences Recent Developments/Updates

Table 85. Mundipharma International Company Information

Table 86. Mundipharma International Description and Business Overview

Table 87. Mundipharma International Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 88. Mundipharma International Pegfilgrastim Biosimilar Product

Table 89. Mundipharma International Recent Developments/Updates

Table 90. Biocon Company Information

Table 91. Biocon Description and Business Overview

Table 92. Biocon Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 93. Biocon Pegfilgrastim Biosimilar Product

Table 94. Biocon Recent Developments/Updates

Table 95. Intas Pharmaceuticals Company Information

Table 96. Intas Pharmaceuticals Description and Business Overview

Table 97. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 98. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product

Table 99. Intas Pharmaceuticals Recent Developments/Updates

Table 100. Pfizer Company Information

Table 101. Pfizer Description and Business Overview

Table 102. Pfizer Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 103. Pfizer Pegfilgrastim Biosimilar Product

Table 104. Pfizer Recent Developments/Updates

Table 105. Dr Reddy’s Laboratories Company Information

Table 106. Dr Reddy’s Laboratories Description and Business Overview

Table 107. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 108. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product

Table 109. Dr Reddy’s Laboratories Recent Developments/Updates

Table 110. Key Raw Materials Lists

Table 111. Raw Materials Key Suppliers Lists

Table 112. Pegfilgrastim Biosimilar Distributors List

Table 113. Pegfilgrastim Biosimilar Customers List

Table 114. Pegfilgrastim Biosimilar Market Trends

Table 115. Pegfilgrastim Biosimilar Market Drivers

Table 116. Pegfilgrastim Biosimilar Market Challenges

Table 117. Pegfilgrastim Biosimilar Market Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Product Picture of Pegfilgrastim Biosimilar

Figure 2. Global Pegfilgrastim Biosimilar Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Pegfilgrastim Biosimilar Market Share by Type: 2025 & 2032

Figure 4. Chemotherapy Treatment Product Picture

Figure 5. Transplantation Product Picture

Figure 6. Global Pegfilgrastim Biosimilar Market Value by Application (US$ Million), 2021–2032

Figure 7. Global Pegfilgrastim Biosimilar Market Share by Application: 2025 & 2032

Figure 8. Hospital Pharmacies

Figure 9. Mail-Order Pharmacies

Figure 10. Retail Pharmacies

Figure 11. Global Pegfilgrastim Biosimilar Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 12. Global Pegfilgrastim Biosimilar Market Size (US$ Million), 2021–2032

Figure 13. Global Pegfilgrastim Biosimilar Sales (K Units), 2021–2032

Figure 14. Global Pegfilgrastim Biosimilar Average Price (US$/Unit), 2021–2032

Figure 15. Pegfilgrastim Biosimilar Report Years Considered

Figure 16. Pegfilgrastim Biosimilar Sales Share by Manufacturers in 2025

Figure 17. Global Pegfilgrastim Biosimilar Revenue Share by Manufacturers in 2025

Figure 18. Top 5 and Top 10 Global Pegfilgrastim Biosimilar Players: Market Share by Revenue in Pegfilgrastim Biosimilar in 2025

Figure 19. Pegfilgrastim Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 20. Global Pegfilgrastim Biosimilar Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 21. North America Pegfilgrastim Biosimilar Sales Market Share by Country (2021–2032)

Figure 22. North America Pegfilgrastim Biosimilar Revenue Market Share by Country (2021–2032)

Figure 23. United States Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 24. Canada Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 25. Europe Pegfilgrastim Biosimilar Sales Market Share by Country (2021–2032)

Figure 26. Europe Pegfilgrastim Biosimilar Revenue Market Share by Country (2021–2032)

Figure 27. Germany Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 28. France Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 29. U.K. Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 30. Italy Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 31. Russia Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Asia Pacific Pegfilgrastim Biosimilar Sales Market Share by Region (2021–2032)

Figure 33. Asia Pacific Pegfilgrastim Biosimilar Revenue Market Share by Region (2021–2032)

Figure 34. China Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Japan Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. South Korea Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. India Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. Australia Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. China Taiwan Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Indonesia Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Thailand Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Malaysia Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Latin America Pegfilgrastim Biosimilar Sales Market Share by Country (2021–2032)

Figure 44. Latin America Pegfilgrastim Biosimilar Revenue Market Share by Country (2021–2032)

Figure 45. Mexico Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Brazil Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. Argentina Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share by Country (2021–2032)

Figure 49. Middle East and Africa Pegfilgrastim Biosimilar Revenue Market Share by Country (2021–2032)

Figure 50. Turkey Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Saudi Arabia Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. UAE Pegfilgrastim Biosimilar Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Global Sales Market Share of Pegfilgrastim Biosimilar by Type (2021–2032)

Figure 54. Global Revenue Market Share of Pegfilgrastim Biosimilar by Type (2021–2032)

Figure 55. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Type (2021–2032)

Figure 56. Global Sales Market Share of Pegfilgrastim Biosimilar by Application (2021–2032)

Figure 57. Global Revenue Market Share of Pegfilgrastim Biosimilar by Application (2021–2032)

Figure 58. Global Pegfilgrastim Biosimilar Price (US$/Unit) by Application (2021–2032)

Figure 59. Pegfilgrastim Biosimilar Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Pegfilgrastim Biosimilar in 2026? zhanKai

The global market size of Pegfilgrastim Biosimilar in 2026 was 1938 Million USD.

What was the global market size of Pegfilgrastim Biosimilar in 2032? shouQi

What is the annual compound growth rate of the global Pegfilgrastim Biosimilar market size from 2026 to 2032? shouQi

Which companies rank high in the global Pegfilgrastim Biosimilar market? shouQi

Which region is expected to have the highest market share? shouQi

Related Reports

Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published Date: 2026-07-09
Pages: 135
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-10-25
Pages: 149
USD 4900.00
(Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 106
USD 3950.00
(Single User License)
Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pegfilgrastim Biosimilar market size was US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published Date: 2025-02-21
Pages: 77
USD 4250.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published Date: 2025-02-21
Pages: 82
USD 2900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Insights, Forecast to 2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-04-25
Pages: 91
USD 4900.00
(Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-02-07
Pages: 82
USD 2900.00
(Single User License)
Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published Date: 2024-01-11
Pages: 101
USD 3950.00
(Single User License)

Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1827 million in 2025 and is projected to reach US$ 2877 million, growing at a CAGR of 6.8% from 2026 to 2032.
Published: 2026-07-09
Pages: 135
USD 3950.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Pegfilgrastim Biosimilar market is projected to grow from US$ 1721 million in 2024 to US$ 2711 million by 2031, at a CAGR of 6.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-10-25
Pages: 149
USD 4900.00 (Single User License)
Pegfilgrastim Biosimilar- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pegfilgrastim Biosimilar was estimated to be worth US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 106
USD 3950.00 (Single User License)
Global Pegfilgrastim Biosimilar Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pegfilgrastim Biosimilar market size was US$ 1721 million in 2024 and is forecast to a readjusted size of US$ 2711 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Published: 2025-02-21
Pages: 77
USD 4250.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2025
The global market for Pegfilgrastim Biosimilar was valued at US$ 1721 million in the year 2024 and is projected to reach a revised size of US$ 2711 million by 2031, growing at a CAGR of 6.8% during the forecast period.
Published: 2025-02-21
Pages: 82
USD 2900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Insights, Forecast to 2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-04-25
Pages: 91
USD 4900.00 (Single User License)
Global Pegfilgrastim Biosimilar Market Research Report 2024
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-02-07
Pages: 82
USD 2900.00 (Single User License)
Pegfilgrastim Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Published: 2024-01-11
Pages: 101
USD 3950.00 (Single User License)